5,370
Views
21
CrossRef citations to date
0
Altmetric
Back Matter

Development of CAR-T cell therapy for B-ALL using a point-of-care approach

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Article: 1752592 | Received 08 Oct 2019, Accepted 31 Mar 2020, Published online: 17 Apr 2020
 

ABSTRACT

Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and face bottlenecks like complex scaling up, high costs, and logistic operations. These difficulties are mainly related to the use of viral vectors and the requirement to expand CAR-T cells to reach the therapeutic dose. In this paper, by using Sleeping Beauty-mediated genetic modification delivered by electroporation, we show that CAR-T cells can be generated and used without the need for ex vivo activation and expansion, consistent with a point-of-care (POC) approach. Our results show that minimally manipulated CAR-T cells are effective in vivo against RS4;11 leukemia cells engrafted in NSG mice even when inoculated after only 4 h of gene transfer. In an effort to better characterize the infused CAR-T cells, we show that 19BBz T lymphocytes infused after 24 h of electroporation (where CAR expression is already detectable) can improve the overall survival and reduce tumor burden in organs of mice engrafted with RS4;11 or Nalm-6 B cell leukemia. A side-by-side comparison of POC approach with a conventional 8-day expansion protocol using Transact beads demonstrated that both approaches have equivalent antitumor activity in vivo. Our data suggest that POC approach is a viable alternative for the generation and use of CAR-T cells, overcoming the limitations of current manufacturing protocols. Its use has the potential to expand CAR immunotherapy to a higher number of patients, especially in the context of low-income countries.

Author contributions

L.M.A., performed the experiments, analyzed the data, and wrote the manuscript. L.R.C.B., performed the experiments and wrote the manuscript. L.C., L.V.C.M., M.S.V., P.S.F. performed the experiments. L.C. and M.H.B. conceived the project, wrote the manuscript and revised the final text.

Acknowledgments

INCA’s blood bank and hemotherapy service were instrumental in this work due to the preparation of donor samples.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Supplementary material

Supplemental data for this article can be accessed on the publisher’s website.

Additional information

Funding

Funding for this study was provided by the Brazilian Ministry of Health, Brazilian National Cancer Institute (INCA), CNPq, CAPES, INCT Synthetic Biology (465603/2014-9), Ary Frauzino Cancer Foundation (FAF), Oncobiology Program – UFRJ, INOVA FIOCRUZ program, ICGEB/CNPq (405231/2015-6).